{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:06:28Z","timestamp":1790521588724,"version":"4.1.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2018,4,25]],"date-time":"2018-04-25T00:00:00Z","timestamp":1524614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7,30]]},"DOI":"10.1093\/ecco-jcc\/jjy050","type":"journal-article","created":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T02:57:53Z","timestamp":1524106673000},"page":"930-938","source":"Crossref","is-referenced-by-count":21,"title":["Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn\u2019s Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN\/ADHERE Trials"],"prefix":"10.1093","volume":"12","author":[{"given":"Remo","family":"Panaccione","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J","family":"Sandborn","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of California San Diego School of Medicine, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"D\u2019Haens","sequence":"additional","affiliation":[{"name":"Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas C","family":"Wolf","sequence":"additional","affiliation":[{"name":"Atlanta Gastroenterology Associates, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Berg","sequence":"additional","affiliation":[{"name":"AbbVie AB, Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-fue","family":"Maa","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Petersson","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M","family":"Robinson","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,4,25]]},"reference":[{"key":"key\n\t\t\t\t20180730065934_CIT0001","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1155\/2015\/815820","article-title":"Living with inflammatory bowel disease: a Crohn\u2019s and Colitis Canada survey","volume":"29","author":"Becker","year":"2015","journal-title":"Can J Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180730065934_CIT0002","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1053\/j.gastro.2013.10.047","article-title":"American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-\u03b1 biologic drugs for the induction and maintenance of remission in inflammatory Crohn\u2019s disease","volume":"145","author":"Terdiman","year":"2013","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180730065934_CIT0003","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"3rd European evidence-based Consensus on the diagnosis and management of Crohn\u2019s disease 2016: part 1: diagnosis and medical management","volume":"11","author":"Gomoll\u00f3n","year":"2017","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20180730065934_CIT0004","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.crohns.2009.12.002","article-title":"The second European evidence-based Consensus on the diagnosis and management of Crohn\u2019s disease: current management","volume":"4","author":"Dignass","year":"2010","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20180730065934_CIT0005","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/apt.13083","article-title":"Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed","volume":"41","author":"Gisbert","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180730065934_CIT0006","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/MEG.0000000000000378","article-title":"Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn\u2019s disease: a systematic review and clinician surveys","volume":"27","author":"Gordon","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180730065934_CIT0007","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180730065934_CIT0008","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180730065934_CIT0009","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180730065934_CIT0010","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn\u2019s disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"key\n\t\t\t\t20180730065934_CIT0011","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180730065934_CIT0012","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/j.1365-2036.2010.04304.x","article-title":"Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn\u2019s disease","volume":"31","author":"Panaccione","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180730065934_CIT0013","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","article-title":"Adalimumab induces and maintains mucosal healing in patients with Crohn\u2019s disease: data from the EXTEND trial","volume":"142","author":"Rutgeerts","year":"2012","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180730065934_CIT0014","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/apt.12499","article-title":"Adalimumab maintains remission of Crohn\u2019s disease after up to 4 years of treatment: data from CHARM and ADHERE","volume":"38","author":"Panaccione","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180730065934_CIT0015","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.cgh.2013.06.019","article-title":"Adalimumab induces deep remission in patients with Crohn\u2019s disease","volume":"12","author":"Colombel","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180730065934_CIT0016","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1111\/j.1572-0241.2004.40462.x","article-title":"An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn\u2019s disease","volume":"99","author":"Sandborn","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20180730065934_CIT0017","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/00054725-200407000-00002","article-title":"A pilot study of adalimumab in infliximab-allergic patients","volume":"10","author":"Youdim","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20180730065934_CIT0018","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2036.2006.03232.x","article-title":"Efficacy and safety of short-term adalimumab treatment in patients with active Crohn\u2019s disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial","volume":"25","author":"Hinojosa","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180730065934_CIT0019","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1365-2036.2009.04101.x","article-title":"Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab","volume":"30","author":"Ma","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180730065934_CIT0020","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1365-2036.2008.03902.x","article-title":"Adalimumab for Crohn\u2019s disease with intolerance or lost response to infliximab: a 3-year single-centre experience","volume":"29","author":"Oussalah","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180730065934_CIT0021","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1155\/2011\/724813","article-title":"Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn\u2019s disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn\u2019s DiseaSe [ACCESS] trial","volume":"25","author":"Panaccione","year":"2011","journal-title":"Can J Gastroenterol"},{"key":"key\n\t\t\t\t20180730065934_CIT0022","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/MEG.0b013e32836220ab","article-title":"Adalimumab for Crohn\u2019s disease after infliximab treatment failure: a systematic review","volume":"25","author":"Da","year":"2013","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180730065934_CIT0023","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1365-2036.2010.04360.x","article-title":"Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn\u2019s disease","volume":"32","author":"Hanauer","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180730065934_CIT0024","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.cgh.2010.04.021","article-title":"Certolizumab pegol in patients with moderate to severe Crohn\u2019s disease and secondary failure to infliximab","volume":"8","author":"Sandborn","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180730065934_CIT0025","first-page":"107","article-title":"Switching between TNFalpha antagonists in rheumatoid arthritis: personal experience and review of the literature","volume":"61","author":"Scrivo","year":"2009","journal-title":"Reumatismo"},{"key":"key\n\t\t\t\t20180730065934_CIT0026","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1185\/03007995.2013.779575","article-title":"Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn\u2019s disease","volume":"29","author":"Sandborn","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"key\n\t\t\t\t20180730065934_CIT0027","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","article-title":"Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn\u2019s disease","volume":"72","author":"Burmester","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180730065934_CIT0028","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cgh.2016.03.038","article-title":"Comparative effectiveness and safety of anti-tumor necrosis factor agents in biologic-na\u00efve patients with Crohn\u2019s disease","volume":"14","author":"Singh","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180730065934_CIT0029","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/ibd.20956","article-title":"Adalimumab safety in global clinical trials of patients with Crohn\u2019s disease","volume":"15","author":"Colombel","year":"2009","journal-title":"Inflamm Bowel Dis"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/12\/8\/930\/25177439\/jjy050.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T01:20:53Z","timestamp":1571188853000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/12\/8\/930\/4985473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,25]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,4,25]]},"published-print":{"date-parts":[[2018,7,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy050","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,8]]},"published":{"date-parts":[[2018,4,25]]}}}